On the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP Peptides

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Tomasello, Marianna Flora ^a   Sinopoli, Alessandro ^b   Pappalardo, Giuseppe ^a  

^a CNR   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; CALCIUM; OLIGOMER; TRANSITION ELEMENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; CALCIUM HOMEOSTASIS; CONFORMATIONAL TRANSITION; ENVIRONMENTAL FACTOR; HUMAN; MEMBRANE; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN UNFOLDING; SINGLE STRAND CONFORMATION POLYMORPHISM; METABOLISM; PANCREAS ISLET; PROTEIN CONFORMATION;

DIABETES MELLITUS, TYPE 2; HUMANS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 84947460158     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/918573     Document Type: Article

References (195)

1. M. Kitada, Z. Zhang, A. Mima, and G. L. King, "Molecular mechanisms of diabetic vascular complications," Journal of Diabetes Investigation, vol. 1, no. 3, pp. 77-89, 2010.
2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," Diabetes Care, vol. 27,no. 5, pp. 1047-1053, 2004.
3. A. Clark, E. J. P. De Koning, A.T. Hattersley, B. C. Hansen,C. S. Yajnik, and J. Poulton, "Pancreatic pathology in non-insulin dependent diabetes (NIDDM)," Diabetes Research and Clinical Practice, vol. 28, pp. S39-S47, 1995.
4. J. W. M. Höppener, B. Ahrén, and C. J. M. Lips, "Islet amyloid and type 2 diabetes mellitus," The New England Journal of Medicine, vol. 343, no. 6, pp. 411-419, 2000.
5. A. S. Detoma, S. Salamekh, A. Ramamoorthy, andM. H. Lim, "Misfolded proteins in Alzheimer's disease and type II diabetes," Chemical Society Reviews, vol. 41, no. 2, pp. 608-621, 2012.
6. K. H. Johnson, T. D. O'Brien, and P. Westermark, "Newly identified pancreatic protein islet amyloid polypeptide: what is its relationship to diabetes?" Diabetes, vol. 40, no. 3, pp. 310-314, 1991.
7. T. Sanke, G. I. Bell, C. Sample, A. H. Rubenstein, and D. F. Steiner, "An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing," Journal of Biological Chemistry, vol. 263, no. 33, pp. 17243-17246, 1988.
8. L. Marzban,G. Trigo-Gonzalez, and C. B. Verchere, "Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of β cells," Molecular Endocrinology, vol. 19, no. 8, pp. 2154-2163, 2005.
9. S. E. Kahn, D. A. D'Alessio, M.W. Schwartz et al., "Evidence of cosecretion of islet amyloid polypeptide and insulin bv β-cells," Diabetes, vol. 39, no. 5, pp. 634-638, 1990.
10. L. M. McLatchie,N. J. Fraser, M. J. Main et al., "RAMPS regulate the transport and ligand specificity of the calcitonin-receptorlike receptor," Nature, vol. 393, no. 6683, pp. 333-339, 1998.
11. R. Muff, N. Bühlmann, J. A. Fischer, and W. Born, "An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or-3," Endocrinology, vol. 140, no. 6, pp. 2924-2927, 1999.
12. D. R. Poyner, P. M. Sexton, I. Marshall et al., "International Union of Pharmacology. XXXII: the mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors," Pharmacological Reviews, vol. 54, no. 2, pp. 233-246, 2002.
13. T. A. Lutz, "The role of amylin in the control of energy homeostasis," The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 298, no. 6, pp. R1475-R1484, 2010.
14. P. Westermark, A. Andersson, and G. T. Westermark, "Islet amyloid polypeptide, islet amyloid, and diabetes mellitus," Physiological Reviews, vol. 91, no. 3, pp. 795-826, 2011.
15. J. Montane, A. Klimek-Abercrombie, K. J. Potter, C. Westwell-Roper, and C. B. Verchere, "Metabolic stress, IAPP and islet amyloid," Diabetes, Obesity and Metabolism, vol. 14, no. 3, pp. 68-77, 2012.
16. Z.-L. Wang,W.M. Bennet, M. A. Ghatei, P.G.H. Byfield, D. M. Smith, and S. R. Bloom, "Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets," Diabetes, vol. 42,no. 2, pp. 330-335, 1993.
17. A. Young, "Inhibition of insulin secretion," Advances in Pharmacology, vol. 52, pp. 173-192, 2005.
18. T. Riediger, M. Rauch, and H. A. Schmid, "Actions of amylin on subfornical organ neurons and on drinking behavior in rats," American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 276, no. 2, pp. R514-R521, 1999.
19. R. D. Reidelberger, A. C. Haver, U. Arnelo, D. D. Smith, C. S. Schaffert, and J. Permert, "Amylin receptor blockade stimulates food intake in rats," American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 287, no. 3, pp. R568-R574, 2004.
20. C. S. Potes and T. A. Lutz, "Brainstem mechanisms of amylininduced anorexia," Physiology and Behavior, vol. 100, no. 5, pp. 511-518, 2010.
21. J. L. Trevaskis, D. G. Parkes, and J. D. Roth, "Insights into amylin-leptin synergy," Trends in Endocrinology and Metabolism, vol. 21, no. 8, pp. 473-479, 2010.
22. A. Abedini and A.M. Schmidt, "Mechanisms of islet amyloidosis toxicity in type 2 diabetes," FEBS Letters, vol. 587, no. 8, pp. 1119-1127, 2013.
23. P. Westermark, U. Engstrom, K. H. Johnson, G. T. Westermark, andC. Betsholtz, "Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 13, pp. 5036-5040, 1990.
24. C. Betsholtz, L. Christmansson, U. Engstrom et al., "Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species," FEBS Letters, vol. 251, no. 1-2, pp. 261-264, 1989.
25. S. J. Wimalawansa, "Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily," Critical Reviews in Neurobiology, vol. 11, no. 2-3, pp. 167-239, 1997.
26. A. Abedini, F. Meng, and D. P. Raleigh, "A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor," Journal of the American Chemical Society, vol. 129, no. 37, pp. 11300-11301, 2007.
27. F. Meng, D. P. Raleigh, and A. Abedini, "Combination of kinetically selected inhibitors in Trans leads to highly effective inhibition of amyloid formation," Journal of the American Chemical Society, vol. 132, no. 41, pp. 14340-14342, 2010.
28. L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu, "Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2046-2051, 2006.
29. A. Abedini and D. P. Raleigh, "Destabilization of human IAPP amyloid fibrils by prolinemutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP?" Journal of Molecular Biology, vol. 355, no. 2, pp. 274-281, 2006.
30. B. W. Koo, J. A. Hebda, and A. D. Miranker, "Amide inequivalence in the fibrillar assembly of islet amyloid polypeptide," Protein Engineering, Design and Selection, vol. 21, no. 3, pp. 147-154, 2008.
31. A. Fox, T. Snollaerts, C. Errecart Casanova, A. Calciano, L. A. Nogaj, and D. A. Moffet, "Selection for nonamyloidogenic mutants of islet Amyloid Polypeptide (IAPP) identifies an extended region for amyloidogenicity," Biochemistry, vol. 49,no. 36, pp. 7783-7789, 2010.
32. M. Magzoub and A. D. Miranker, "Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide," FASEB Journal, vol. 26, no. 3, pp. 1228-1238, 2012.
33. M. F. Tomasello, A. Sinopoli, F. Attanasio et al., "Molecular and cytotoxic properties of hIAPP17-29 and rIAPP17-29 fragments: a comparative study with the respective full-length parent polypeptides," European Journal ofMedicinal Chemistry, vol. 81, pp. 442-455, 2014.
34. J. R. Brender, S. Salamekh, and A. Ramamoorthy, "Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective," Accounts of Chemical Research, vol. 45, no. 3, pp. 454-462, 2012.
35. N. A. Bernhardt, W. M. Berhanu, and U. H. E. Hansmann, "Mutations and seeding of amylin fibril-like oligomers," Journal of Physical Chemistry B, vol. 117, no. 50, pp. 16076-16085, 2013.
36. A. Clark, D. R. Matthews, B. A. Naylor, C. A. Wells, J. P. Hosker, and R. C. Turner, "Pancreatic islet amyloid and elevated proinsulin secretion in familial maturity-onset diabetes," Diabetes Research, vol. 4, no. 2, pp. 51-55, 1987.
37. S. Luca, W.-M. Yau, R. Leapman, and R. Tycko, "Peptide conformation and supramolecular organization in amylin fibrils: constraints fromsolid-stateNMR," Biochemistry, vol. 46, no. 47, pp. 13505-13522, 2007.
38. A. V. Kajava, U. Aebi, and A. C. Steven, "The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin," Journal of Molecular Biology, vol. 348, no. 2, pp. 247-252, 2005.
39. M. F. M. Engel, "Membrane permeabilization by Islet Amyloid Polypeptide," Chemistry and Physics of Lipids, vol. 160, no. 1, pp. 1-10, 2009.
40. K. Sasahara, K. Morigaki, and K. Shinya, "Amyloid aggregation and deposition of human islet amyloid polypeptide at membrane interfaces," FEBS Journal, vol. 281, no. 11, pp. 2597-2612, 2014.
41. N. B. Last and A. D. Miranker, "Common mechanism unites membrane poration by amyloid and antimicrobial peptides," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 16, pp. 6382-6387, 2013.
42. T. A. Mirzabekov, M.-C. Lin, and B. L. Kagan, "Pore formation by the cytotoxic islet amyloid peptide amylin," Journal of Biological Chemistry, vol. 271, no. 4, pp. 1988-1992, 1996.
43. P. Cao, P. Marek, H. Noor et al., "Islet amyloid: fromfundamental biophysics to mechanisms of cytotoxicity," FEBS Letters, vol. 587, no. 8, pp. 1106-1118, 2013.
44. M. Wakabayashi and K. Matsuzaki, "Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts," FEBS Letters, vol. 583, no. 17, pp. 2854-2858, 2009.
45. S. Trikha and A. M. Jeremic, "Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasmamembrane cholesterol,"The Journal of Biological Chemistry, vol. 286, no. 41, pp. 36086-36097, 2011.
46. J. Seeliger, K. Weise, N. Opitz, and R. Winter, "The effect of Aβ on IAPP aggregation in the presence of an isolated β-cellmembrane," Journal of Molecular Biology, vol. 421, no. 2-3, pp. 348-363, 2012.
47. J.D. Knight, J. A. Williamson, andA. D. Miranker, "Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin," Protein Science, vol. 17,no. 10,pp. 1850-1856, 2008.
48. W.-J. Cho, S. Trikha, and A. M. Jeremic, "Cholesterol regulates assembly of human islet amyloid polypeptide on model membranes," Journal of Molecular Biology, vol. 393, no. 3, pp. 765-775, 2009.
49. K. Weise, D. Radovan, A. Gohlke, N. Opitz, and R. Winter, "Interaction of hIAPP with model raft membranes and pancreatic β-cells: cytotoxicity of hIAPP oligomers," ChemBioChem, vol. 11, no. 9, pp. 1280-1290, 2010.
50. G. P. Gellermann, T. R. Appel, A. Tannert et al., "Raft lipids as common components of human extracellular amyloid fibrils," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 18, pp. 6297-6302, 2005.
51. M. F. M. Engel, H. Yigittop, R. C. Elgersma et al., "Islet amyloid polypeptide inserts into phospholipid monolayers as monomer," Journal of Molecular Biology, vol. 356, no. 3, pp. 783-789, 2006.
52. R. P. R. Nanga, J. R. Brender, J. Xu,G. Veglia, andA. Ramamoorthy, "Structures of rat and human islet amyloid polypeptide IAPP1-19 in micelles by NMR spectroscopy," Biochemistry, vol. 47, no. 48, pp. 12689-12697, 2008.
53. R. P. R. Nanga, J. R. Brender, J. Xu,K. Hartman,V. Subramanian, andA. Ramamoorthy, "Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy," Journal of the American Chemical Society, vol. 131, no. 23, pp. 8252-8261, 2009.
54. S. M. Patil, S. Xu, S. R. Sheftic, and A. T. Alexandrescu, "Dynamic β-helix structure of micelle-bound human amylin," Journal of Biological Chemistry, vol. 284, no. 18, pp. 11982-11991, 2009.
55. M. Apostolidou, S. A. Jayasinghe, and R. Langen, "Structure of β-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding," Journal of Biological Chemistry, vol. 283, no. 25, pp. 17205-17210, 2008.
56. S. A. Jayasinghe and R. Langen, "Membrane interaction of islet amyloid polypeptide," Biochimica et Biophysica Acta-Biomembranes, vol. 1768, no. 8, pp. 2002-2009, 2007.
57. J. R. Brender, D. L. Heyl, S. Samisetti et al., "Membrane disordering is not sufficient for membrane permeabilization by islet amyloid polypeptide: studies of IAPP(20-29) fragments," Physical Chemistry Chemical Physics, vol. 15, no. 23, pp. 8908-8915, 2013.
58. M. F. M. Sciacca, J. R. Brender,D.-K. Lee, and A. Ramamoorthy, "Phosphatidylethanolamine enhances amyloid fiber-dependent membrane fragmentation," Biochemistry, vol. 51, no. 39, pp. 7676-7684, 2012.
59. R. P. R. Nanga, J. R. Brender, S. Vivekanandan, and A. Ramamoorthy, "Structure and membrane orientation of IAPP in its natively amidated format physiologicalpHin amembrane environment," Biochimica et Biophysica Acta-Biomembranes, vol. 1808, no. 10, pp. 2337-2342, 2011.
60. J. R. Brender, J. Krishnamoorthy, G. M. L. Messina et al., "Zinc stabilization of prefibrillar oligomers of human islet amyloid polypeptide," Chemical Communications, vol. 49, no. 32, pp. 3339-3341, 2013.
61. J. R. Brender, E. L. Lee, K. Hartman et al., "Biphasic effects of insulin on islet amyloid polypeptide membrane disruption," Biophysical Journal, vol. 100, no. 3, pp. 685-692, 2011.
62. A. Abedini and D. P. Raleigh, "The role of His-18 in amyloid formation by human islet amyloid polypeptide," Biochemistry, vol. 44, no. 49, pp. 16284-16291, 2005.
63. S. Jha, J. M. Snell, S. R. Sheftic et al., "PH dependence of amylin fibrillization," Biochemistry, vol. 53, no. 2, pp. 300-310, 2014.
64. G. Pappalardo, D. Milardi, A. Magr et al., "Environmental factors differently affect human and rat IAPP: conformational preferences and membrane interactions of IAPP17-29 peptide derivatives," Chemistry, vol. 13, no. 36, pp. 10204-10215, 2007.
65. K. Yanagi, M. Ashizaki, H. Yagi, K. Sakurai, Y. H. Lee, and Y. Goto, "Hexafluoroisopropanol induces amyloid fibrils of islet amyloid polypeptide by enhancing both hydrophobic and electrostatic interactions," The Journal of Biological Chemistry, vol. 286, no. 27, pp. 23959-23966, 2011.
66. S. B. P. Chargé,E. J.P .deKoning, andA. Clark, "Effect of pHand insulin on fibrillogenesis of islet amyloid polypeptide in vitro," Biochemistry, vol. 34, no. 44, pp. 14588-14593, 1995.
67. A. Mazzaglia, N. Micali, L. M. Scolaro et al., "Aggregation properties of the peptide fragments derived from the 17-29 region of the human and rat IAPP: a comparative studywith two PEG-conjugated variants of the human sequence," Journal of Physical Chemistry B, vol. 114, no. 2, pp. 705-713, 2010.
68. J. R. Brender, K. Hartman, R. P. R. Nanga et al., "Role of zinc in human islet amyloid polypeptide aggregation," Journal of the American Chemical Society, vol. 132, no. 26, pp. 8973-8983, 2010.
69. E.D. Harris, "Copper transport: an overview," Proceedings of the Society for Experimental Biology andMedicine, vol. 196, no.2,pp. 130-140, 1991.
70. J. Mayes,C. Tinker-Mill, O. Kolosov, H. Zhang, B. J. Tabner, and D. J. Allsop, "β-amyloid fibrils in Alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species," The Journal of Biological Chemistry, vol. 289, no. 17, pp. 12052-12062, 2014.
71. P. Faller, C. Hureau, and G. la Penna, "Metal ions and intrinsically disordered proteins and peptides: from Cu/Zn amyloid-β to general principles," Accounts of Chemical Research, vol. 47,no. 8, pp. 2252-2259, 2014.
72. B. J. Tabner, S. Turnbull, O. M. A. El-Agnaf, and D. Allsop, "Formation of hydrogen peroxide and hydroxyl radicals from Aβ and β-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease," Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1076-1083, 2002.
73. N. R. Williams, J. Rajput-Williams, J. A. West, S. V. Nigdikar, J. W. Foote, and A. N. Howard, "Plasma, granulocyte and mononuclear cell copper and zinc in patients with diabetes mellitus," The Analyst, vol. 120, no. 3, pp. 887-890, 1995.
74. J. W. Eaton and M. Qian, "Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy," Molecular and Cellular Biochemistry, vol. 234-235, no. 1-2, pp. 135-142, 2002.
75. A. Masad, L. Hayes, B. J. Tabner et al., "Copper-mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus?" FEBS Letters, vol. 581, no. 18, pp. 3489-3493, 2007.
76. A. Masad,B. J. Tabner, J. Mayes, and D. Allsop, "The amylinpeptide implicated in type 2 diabetes stimulates copper-mediated carbonyl group and ascorbate radical formation," Free Radical Biology and Medicine, vol. 51, no. 4, pp. 869-875, 2011.
77. B. J. Tabner, O. M. A. El-Agnaf, S. Turnbull et al., "Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia," Journal of Biological Chemistry, vol. 280, no. 43, pp. 35789-35792, 2005.
78. L. Ma, X. Li, Y. Wang, W. Zheng, and T. Chen, "Cu(II) inhibits hIAPP fibrillation and promotes hIAPP-induced beta cell apoptosis through induction of ROS-mediated mitochondrial dysfunction," Journal of Inorganic Biochemistry, vol. 140, pp. 143-152, 2014.
79. K. A. Jellinger, "The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations," International Review of Neurobiology, vol. 110, pp. 1-47, 2013.
80. M. P. Cuajungco, C. J. Frederickson, and A. I. Bush, "Amyloidbeta metal interaction and metal chelation," Sub-Cellular Biochemistry, vol. 38, pp. 235-254, 2005.
81. E. C. Lee, E. Ha, S. Singh et al., "Copper(II)-human amylin complex protects pancreatic cells from amylin toxicity," Physical Chemistry Chemical Physics, vol. 15, no. 30, pp. 12558-12571, 2013.
82. B. Ward, K. Walker, and C. Exley, "Copper(II) inhibits the formation of amylin amyloid in vitro," Journal of Inorganic Biochemistry, vol. 102, no. 2, pp. 371-375, 2008.
83. Y.P. Yu, P. Lei, J. Hu,W.H. Wu, Y. F. Zhao, and Y.M. Li, "Copperinduced cytotoxicity: reactive oxygen species or islet amyloid polypeptide oligomer formation," Chemical Communications, vol. 46, no. 37, pp. 6909-6911, 2010.
84. A. Sinopoli, A. Magr, D. Milardi et al., "The role of copper(II) in the aggregation of human amylin," Metallomics, vol. 6, no. 10, pp. 1841-1852, 2014.
85. C. Kállay, Á. Dávid, S. Timári et al., "Copper(II) complexes of rat amylin fragments," Dalton Transactions, vol. 40, no. 38, pp. 9711-9721, 2011.
86. M. C. Foster, R. D. Leapman, M. X. Li, and I. Atwater, "Elemental composition of secretory granules in pancreatic islets of Langerhans," Biophysical Journal, vol. 64, no. 2, pp. 525-532, 1993.
87. A. B. Chausmer, "Zinc, insulin, and diabetes," Journal of the American College of Nutrition, vol. 17, no. 2, pp. 109-115, 1998.
88. P. Westermark, Z.-C. Li, G. T. Westermark, A. Leckström, and D. F. Steiner, "Effects of beta cell granule components on human islet amyloid polypeptide fibril formation," FEBS Letters, vol. 379, no. 3, pp. 203-206, 1996.
89. S. Salamekh, J. R. Brender, S.-J. Hyung et al., "A two-site mechanism for the inhibition of IAPP amyloidogenesis by zinc," Journal of Molecular Biology, vol. 410, no. 2, pp. 294-306, 2011.
90. C. G. Taylor, "Zinc, the pancreas, and diabetes: insights from rodent studies and future directions," BioMetals, vol. 18, no. 4, pp. 305-312, 2005.
91. G. Dodson and D. Steiner, "The role of assembly in insulin's biosynthesis," Current Opinion in Structural Biology, vol. 8, no. 2, pp. 189-194, 1998.
92. X. F. Huang and P. Arvan, "Intracellular transport of proinsulin in pancreatic beta-cells. Structural maturation probed bydisulfide accessibility," Journal of Biological Chemistry, vol. 270, no. 35, pp. 20417-20423, 1995.
93. K. Lemaire, M. A. Ravier, A. Schraenen et al., "Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 35, pp. 14872-14877, 2009.
94. J. Janson,W. C. Soeller, P. C. Roche et al., "Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 14, pp. 7283-7288, 1996.
95. A. Lorenzo, B. Razzaboni, G. C. Weir, and B. A. Yankner, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus," Nature, vol. 368, no. 6473, pp. 756-760, 1994.
96. S. E. Kahn, S. Andrikopoulos, and C. B. Verchere, "Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes," Diabetes, vol. 48, no. 2, pp. 241-253, 1999.
97. A. E. Butler, J. Janson,W. C. Soeller, and P. C. Butler, "Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid," Diabetes, vol. 52, no. 9, pp. 2304-2314, 2003.
98. B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, and G. J. S. Cooper, "The aggregation potential of human amylin determines its cytotoxicity towards islet β-cells," FEBS Journal, vol. 273, no. 15, pp. 3614-3624, 2006.
99. G. Acocella, "Clinical pharmacokinetics of rifampicin," Clinical Pharmacokinetics, vol. 3, no. 2, pp. 108-127, 1978.
100. G. Bates, "Huntingtin aggregation and toxicity in Huntington's disease," The Lancet, vol. 361, no. 9369, pp. 1642-1644, 2003.
101. J. J. Meier, R. Kayed, C.-Y. Lin et al., "Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP," The American Journal of Physiology-Endocrinology and Metabolism, vol. 291, no. 6, pp. E1317-E1324, 2006.
102. C. G. Glabe and R. Kayed, "Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis," Neurology, vol. 66, no. 2, supplement 1, pp. S74-S78, 2006.
103. S. E. Lesné, M. A. Sherman, M. Grant et al., "Brain amyloid-β oligomers in ageing and Alzheimer's disease," Brain, vol. 136, no. 5, pp. 1383-1398, 2013.
104. Y. Bram, A. Frydman-Marom, I. Yanai et al., "Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies," Scientific Reports, vol. 4, article 4267, 2014.
105. H.-L. Zhao, Y. Sui, J. Guan et al., "Amyloid oligomers in diabetic and nondiabetic human pancreas," Translational Research, vol. 153, no. 1, pp. 24-32, 2009.
106. R. A. Ritzel, J. J. Meier, C.-Y. Lin, J. D. Veldhuis, and P. C. Butler, "Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets," Diabetes, vol. 56, no. 1, pp. 65-71, 2007.
107. S. P. Zhang, J. X. Liu, M. Dragunow, and G. J. S. Cooper, "Fibrillogenic amylin evokes islet β-cell apoptosis through linked activation of a caspase cascade and JNK1," The Journal of Biological Chemistry, vol. 278, no. 52, pp. 52810-52819, 2003.
108. S. P. Zhang, J. X. Liu, E. L. Saafi, and G. J. S. Cooper, "Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21(WAF1/CIP1)," FEBS Letters, vol. 455, no. 3, pp. 315-320, 1999.
109. M. Couce, L. A. Kane, T. D. O'Brien et al., "Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and β-cell dysfunction," Diabetes, vol. 45, no. 8, pp. 1094-1101, 1996.
110. C. B. Verchere, D. A. D'Alessio, R. D. Palmiter et al., "Islet amyloid formation associated with hyperglycemia in transgenic micewith pancreatic beta cell expression of human islet amyloid polypeptide," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3492-3496, 1996.
111. T. Gurlo, S. Ryazantsev, C.-J. Huang et al., "Evidence for proteotoxicity in β cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway," The American Journal of Pathology, vol. 176, no. 2, pp. 861-869, 2010.
112. C.-Y. Lin, T. Gurlo, R. Kayed et al., "Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β-cell apoptosis in h-IAPP transgenic mice," Diabetes, vol. 56, no. 5, pp. 1324-1332, 2007.
113. C.-J. Huang, L. Haataja, T. Gurlo et al., "Induction of endoplasmic reticulum stress-induced β-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide," The American Journal of Physiology-Endocrinology andMetabolism, vol. 293, no.6,pp. E1656-E1662, 2007.
114. L. Khemtémourian, J. A. Killian, J.W. Höppener, and M. F. M. Engel, "Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus," Experimental Diabetes Research, vol. 2008, Article ID 421287, 9 pages, 2008.
115. P. Westermark, "Fine structure of islets of langerhans in insular amyloidosis," Virchows Archiv A, vol. 359, no. 1, pp. 1-18, 1973.
116. E. L. Saafi, B. Konarkowska, S. Zhang, J. Kistler, and G. J. S. Cooper, "Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells," Cell Biology International, vol. 25, no. 4, pp. 339-350, 2001.
117. M. Anguiano, R. J. Nowak, and P.T. Lansbury Jr., "Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes," Biochemistry, vol. 41, no. 38, pp. 11338-11343, 2002.
118. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C. Butler, "The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles," Diabetes, vol. 48, no. 3, pp. 491-498, 1999.
119. Y. Porat, S. Kolusheva, R. Jelinek, and E. Gazit, "The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies," Biochemistry, vol. 42, no. 37, pp. 10971-10977, 2003.
120. R. Kayed, Y. Sokolov, B. Edmonds et al., "Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases," The Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363-46366, 2004.
121. R. Kayed, J. Bernhagen, N. Greenfield et al., "Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro," Journal of Molecular Biology, vol. 287, no. 4, pp. 781-796, 1999.
122. S. Gilead, H. Wolfenson, and E. Gazit, "Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin," Angewandte Chemie-International Edition, vol. 45, no. 39, pp. 6476-6480, 2006.
123. E. T. A. S. Jaikaran, M. R. Nilsson, and A. Clark, "Pancreatic β-cell granule peptides formheteromolecular complexes which inhibit islet amyloid polypeptide fibril formation," Biochemical Journal, vol. 377, no. 3, pp. 709-716, 2004.
124. I. Rustenbeck, A. Matthies, and S. Lenzen, "Lipid composition of glucose-stimulated pancreatic islets and insulin-secreting tumor cells," Lipids, vol. 29, no. 10, pp. 685-692, 1994.
125. S. A. Jayasinghe andR. Langen, "Lipidmembranesmodulate the structure of islet amyloid polypeptide," Biochemistry, vol. 44,no. 36, pp. 12113-12119, 2005.
126. J. D. Knight and A. D. Miranker, "Phospholipid catalysis of diabetic amyloid assembly," Journal of Molecular Biology, vol. 341, no. 5, pp. 1175-1187, 2004.
127. J. D. Knight, J. A. Hebda, and A. D. Miranker, "Conserved and cooperative assembly of membrane-bound β-helical states of islet amyloid polypeptide," Biochemistry, vol. 45, no. 31, pp. 9496-9508, 2006.
128. E. Sparr, M. F. M. Engel, D. V. Sakharov et al., "Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers," FEBS Letters, vol. 577, no. 1-2, pp. 117-120, 2004.
129. T. Konno, S. Oiki, and T. Morii, "Synergistic action of polyanionic and non-polar cofactors in fibrillation of human islet amyloid polypeptide," FEBS Letters, vol. 581, no. 8, pp. 1635-1638, 2007.
130. A. M. Ruschak and A. D. Miranker, "Fiber-dependent amyloid formation as catalysis of an existing reaction pathway," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 30, pp. 12341-12346, 2007.
131. S. Jha, S. M. Patil, J. Gibson, C. E. Nelson, N. N. Alder, and A. T. Alexandrescu, "Mechanism of amylin fibrillization enhancement by heparin,"The Journal of Biological Chemistry, vol. 286, no. 26, pp. 22894-22904, 2011.
132. M. Wogulis, S. Wright, D. Cunningham, T. Chilcote, K. Powell, and R. E. Rydel, "Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death," Journal of Neuroscience, vol. 25, no. 5, pp. 1071-1080, 2005.
133. M. Kawahara, Y. Kuroda, N. Arispe, and E. Rojas, "Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell lin," The Journal of Biological Chemistry, vol. 275, no. 19, pp. 14077-14083, 2000.
134. M. P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg, and R. E. Rydel, "β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity," Journal of Neuroscience, vol. 12, no. 2, pp. 376-389, 1992.
135. M. F. M. Sciacca, D. Milardi, G. M. L. Messina et al., "Cations as switches of amyloid-mediated membrane disruption mechanisms: calcium and IAPP," Biophysical Journal, vol. 104, no. 1, pp. 173-184, 2013.
136. P. Gilon, H. Y. Chae, G. A. Rutter, and M. A. Ravier, "Calcium signaling in pancreatic β-cells in health and in Type 2 diabetes," Cell Calcium, vol. 56, no. 5, pp. 340-361, 2014.
137. M. Salas, R. A. Silvestre, O. Garcia-Hermida, T. Fontela, J. Rodriguez-Gallardo, and J. Marco, "Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli. Study in perfused rat pancreas,"Diabete etMetabolisme, vol. 21, no. 4, pp. 269-273, 1995.
138. H. Ohsawa, A. Kanatsuka, T. Yamaguchi, H. Makino, and S. Yoshida, "Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion fromisolated rat pancreatic islets," Biochemical and Biophysical Research Communications, vol. 160, no. 2, pp. 961-967, 1989.
139. T. Zhu,Y. Wang, B.He, J.Zang,Q. He, and W. Zhang, "Islet amyloid polypeptide acts on glucose-stimulated beta cells to reduce voltage-gated calcium channel activation, intracellular Ca2+ concentration, and insulin secretion," Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 28-34, 2011.
140. M. Soty,M. Visa, S. Soriano, M. D. C. Carmona, Á. Nadal, and A. Novials, "Involvement of ATP-sensitive potassium (K ATP) channels in the loss of beta-cell function induced by human islet amyloid polypeptide,"The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40857-40866, 2011.
141. B. J. Blanchard, A. Chen, L. M. Rozeboom, K. A. Stafford, P. Weigele, and V. M. Ingram, "Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a smallmolecule," Proceedings of theNational Academy of Sciences of the United States of America, vol. 101, no. 40, pp. 14326-14332, 2004.
142. S. Casas, R. Gomis, F.M. Gribble, J. Altirriba, S. Knuutila, andA. Novials, "Impairment of the ubiquitin-proteasome pathway is a downstreamendoplasmic reticulumstress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis," Diabetes, vol. 56, no. 9, pp. 2284-2294, 2007.
143. R. L. Hull, S. Zraika, J. Udayasankar, K. Aston-Mourney, S. L. Subramanian, and S. E. Kahn, "Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress," Diabetologia, vol. 52, no. 6, pp. 1102-1111, 2009.
144. D. Scheuner and R. J. Kaufman, "The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes," Endocrine Reviews, vol. 29, no. 3, pp. 317-333, 2008.
145. Y. C. Kudva, C. Mueske, P. C. Butler, and N. L. Eberhardt, "A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation," Biochemical Journal, vol. 331, part 3, pp. 809-813, 1998.
146. Y. Ishida, A. Yamamoto, A. Kitamura et al., "Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulumas a means of cell protection,"Molecular Biology of the Cell, vol. 20, no. 11, pp. 2744-2754, 2009.
147. V. Kirkin, D. G. McEwan, I. Novak, and I. Dikic, "A role for ubiquitin in selective autophagy," Molecular Cell, vol. 34, no. 3, pp. 259-269, 2009.
148. N. Mizushima and M. Komatsu, "Autophagy: renovation of cells and tissues," Cell, vol. 147, no. 4, pp. 728-741, 2011.
149. W. H. Yu, A. M. Cuervo, A. Kumar et al., "Macroautophagy-a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease," Journal of Cell Biology, vol. 171, no. 1, pp. 87-98, 2005.
150. J. Kim, H. Cheon, Y. T. Jeong et al., "Amyloidogenic peptide oligomer accumulation in autophagy-deficient β cells induces diabetes,"The Journal of Clinical Investigation, vol. 124, no. 8, pp. 3311-3324, 2014.
151. N. Shigihara, A. Fukunaka, A. Hara et al., "Human IAPPinduced pancreatic β cell toxicity and its regulation by autophagy," Journal of Clinical Investigation, vol. 124, no. 8, pp. 3634-3644, 2014.
152. M. Stefani and C. M. Dobson, "Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution," Journal of Molecular Medicine, vol. 81, no. 11, pp. 678-699, 2003.
153. J. D. Acharya and S. S. Ghaskadbi, "Islets and their antioxidant defense," Islets, vol. 2, no. 4, pp. 225-235, 2010.
154. S. Zraika, R. L. Hull, J. Udayasankar et al., "Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis," Diabetologia, vol. 52, no. 4, pp. 626-635, 2009.
155. S. L. Subramanian, R. L. Hull, S. Zraika, K. Aston-Mourney, J. Udayasankar, and S. E. Kahn, "cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets," Diabetologia, vol. 55, no. 1, pp. 166-174, 2012.
156. E. S. Levitan, "Signaling for vesicle mobilization and synaptic plasticity," Molecular Neurobiology, vol. 37, no. 1, pp. 39-43, 2008.
157. P. Maechler and C. B. Wollheim, "Mitochondrial function in normal and diabetic β-cells," Nature, vol. 414, no. 6865, pp. 807-812, 2001.
158. G. E. Gibson, S. S. Karuppagounder, and Q. Shi, "Oxidantinduced changes in mitochondria and calcium dynamics in the pathophysiology ofAlzheimer's disease," Annals of the New York Academy of Sciences, vol. 1147, pp. 221-232, 2008.
159. Y.-A. Lim, V. Rhein, G. Baysang et al., "Aβ and human amylin share a common toxicity pathway via mitochondrial dysfunction," Proteomics, vol. 10, no. 8, pp. 1621-1633, 2010.
160. P. Li, D. Nijhawan, I. Budihardjo et al., "Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade," Cell, vol. 91, no. 4, pp. 479-489, 1997.
161. P. Gubellini, B. Picconi,M. di Filippo, and P. Calabresi, "Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1802, no. 1, pp. 151-161, 2010.
162. S. Zhang, J. Liu, G. MacGibbon, M. Dragunow, and G. J. S. Cooper, "Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet β-cells," Journal ofMolecular Biology, vol. 324, no. 2,pp. 271-285, 2002.
163. K. Maedler, G. A. Spinas, R. Lehmann et al., "Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets," Diabetes, vol. 50, no. 8, pp. 1683-1690, 2001.
164. S. Zhang, H. Liu, H. Yu, and G. J. S. Cooper, "Fas-associated death receptor signaling evoked by human amylin in islet betacells," Diabetes, vol. 57, no. 2, pp. 348-356, 2008.
165. N. G. N. Milton and J. R. Harris, "Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide," Micron, vol. 44, no. 1, pp. 246-253, 2013.
166. A. Nath, A. D. Miranker, and E. Rhoades, "A membrane-bound antiparallel dimer of rat islet amyloid polypeptide," Angewandte Chemie, vol. 50, no. 46, pp. 10859-10862, 2011.
167. I. Sebastiaõ, E. Candeias, M. S. Santos C, P. I. Moreira, and A. I. Duarte, "Insulin as a bridge between typer 2 diabets and Alzheimer disease-how antidiabetics could be a solution for dementia," Frontiers in Endocrinology, vol. 5, article 110,pp. 1-13, 2014.
168. Y. Yang and W. Song, "Molecular links between Alzheimer's disease and diabetes mellitus," Neuroscience, vol. 250, pp. 140-150, 2013.
169. L.-M. Yan, A. Velkova, and A. Kapurniotu, "Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide," Current Pharmaceutical Design, vol. 20, no. 8, pp. 1182-1191, 2014.
170. C. E. Higham, E. T. A. S. Jaikaran, P. E. Fraser, M. Gross, and A. Clark, "Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils," FEBS Letters, vol. 470, no. 1, pp. 55-60, 2000.
171. J. R. Brender, E. L. Lee,M. A. Cavitt,A. Gafni, D. G. Steel, andA. Ramamoorthy, "Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide," Journal of the American Chemical Society, vol. 130, no. 20, pp. 6424-6429, 2008.
172. S. Jha, D. Sellin, R. Seidel, and R. Winter, "Amyloidogenic propensities and conformational properties of ProIAPP and IAPP in the presence of lipid bilayer membranes," Journal of Molecular Biology, vol. 389, no. 5, pp. 907-920, 2009.
173. A. Demuro, E. Mina, R. Kayed, S. C. Milton, I. Parker, and C. G. Glabe, "Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers," Journal of Biological Chemistry, vol. 280, no. 17, pp. 17294-17300, 2005.
174. S. A. Kotler, P. Walsh, J. R. Brender, and A. Ramamoorthy, "Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details ofAlzheimer's disease," Chemical Society Reviews, vol. 43, no. 19, pp. 6692-6700, 2014.
175. B. O'Nuallain, A. D. Williams, P. Westermark, and R. Wetzel, ""Seeding specificity in amyloid growth induced by heterologous fibrils,"The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17490-17499, 2004.
176. R. Kayed, E. Head, J. L. Thompson et al., "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis," Science, vol. 300, no. 5618, pp. 486-489, 2003.
177. G. Grasso, M. L. Giuffrida, and E. Rizzarelli, "Metallostasis and amyloid β-degrading enzymes," Metallomics, vol. 4, no. 9, pp. 937-949, 2012.
178. F. Bellia and G. Grasso, "The role of copper(II) and zinc(II) in the degradation of human and murine IAPP by insulindegrading enzyme," Journal ofMass Spectrometry, vol. 49, no. 4, pp. 274-279, 2014.
179. W. Q. Qiu and M. F. Folstein, "Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis," Neurobiology of Aging, vol. 27, no. 2, pp. 190-198, 2006.
180. S. Ayton, P. Lei, and A. I. Bush, "Metallostasis in Alzheimer's disease," Free Radical Biology and Medicine, vol. 62, pp. 76-89, 2013.
181. P. Faller, C. Hureau, and O. Berthoumieu, "Role of metal ions in the self-assembly of the Alzheimer's amyloid-β peptide," Inorganic Chemistry, vol. 52, no. 21, pp. 12193-12206, 2013.
182. G. Arena, G. Pappalardo, I. Sovago, and E. Rizzarelli, "Copper( II) interaction with amyloid-β: affinity and speciation," Coordination Chemistry Reviews, vol. 256, no. 1-2,pp. 3-12, 2012.
183. A. I. Bush, "The metallobiology of Alzheimer's disease," Trends in Neurosciences, vol. 26, no. 4, pp. 207-214, 2003.
184. A. Gnjec, J. A. Fonte, C. Atwood, andR.N. Martins, "Transition metal chelator therapy-a potential treatment for Alzheimer's disease?" Frontiers in Bioscience, vol. 7, pp. 1016-1023, 2002.
185. Z. Kroner, "The relationship between Alzheimer's disease and diabetes: type 3 diabetes?" Alternative Medicine Review, vol. 14, no. 4, pp. 373-379, 2009.
186. L. Li and C. Hölscher, "Common pathological processes in Alzheimer disease and type 2 diabetes: a review," Brain Research Reviews, vol. 56, no. 2, pp. 384-402, 2007.
187. G. S. Desai, C. Zheng, T. Geetha et al., "The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease," Journal of Alzheimer's Disease, vol. 42, no. 2, pp. 347-356, 2014.
188. K. Jackson, G. A. Barisone, E. Diaz, L.-W. Jin, C. DeCarli, and F. Despa, "Amylin deposition in the brain: a second amyloid in Alzheimer disease?" Annals of Neurology, vol. 74, no. 4, pp. 517-526, 2013.
189. M. L. Giuffrida, F. Tomasello, F. Caraci, S. Chiechio, F. Nicoletti, and A. Copani, "Beta-Amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease," Molecular Neurobiology, vol. 46, no. 3, pp. 605-613, 2012.
190. M. L. Giuffrida, F. Caraci, B. Pignataro et al., "Beta-amyloid monomers are neuroprotective," Journal ofNeuroscience, vol. 29, no. 34, pp. 10582-10587, 2009.
191. B. L. Adler, M. Yarchoan,H.M. Hwang et al., "Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition," Neurobiology of Aging, vol. 35, no. 4, pp. 793-801, 2014.
192. W. Q. Qiu and H. Zhu, "Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?" Frontiers in Aging Neuroscience, vol. 6, article 186, 9 pages, 2014.
193. E. Andreetto, L.-M. Yan, A. Caporale, and A. Kapurniotu, "Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Aβ40 amyloid formation and cytotoxicity," ChemBioChem, vol. 12, no. 9, pp. 1313-1322, 2011.
194. J. Seeliger, F. Evers, C. Jeworrek et al., "Cross-amyloid interaction of Aβ and IAPP at lipidmembranes," Angewandte Chemie, vol. 51, no. 3, pp. 679-683, 2012.
195. N. Rezaei-Ghaleh, E. Andreetto, L.-M. Yan, A. Kapurniotu, M. Zweckstetter, and J. Santos, "Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polipeptide," PLoSONE, vol. 6, no. 5,Article IDe20289, 2011.